These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 9020492

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
    Stevens MJ, Norman AR, Dearnaley DP, Horwich A.
    J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
    Inanç SE, Meral R, Darendeliler E, Yasasever V, Onat H.
    Acta Oncol; 1999 Jan; 38(4):505-9. PubMed ID: 10418719
    [Abstract] [Full Text] [Related]

  • 5. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
    Price P, Hogan SJ, Bliss JM, Horwich A.
    Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
    [Abstract] [Full Text] [Related]

  • 6. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [Abstract] [Full Text] [Related]

  • 7. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH, Sleijfer DT, Schraffordt Koops H, De Bruijn HW, Oosterhuis JW, Brouwers TM, Ockhuizen T, Marrink J.
    Oncodev Biol Med; 1981 Dec; 2(1-2):129-34. PubMed ID: 6170953
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
    Christensen TB, Engbaek F, Marqversen J, Nielsen SI, Kamby C, von der Maase H.
    Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
    [Abstract] [Full Text] [Related]

  • 10. Serum tumour marker regression rate following chemotherapy for malignant teratoma.
    Horwich A, Peckham MJ.
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1463-70. PubMed ID: 6209145
    [Abstract] [Full Text] [Related]

  • 11. Prognosis following chemotherapy for metastatic malignant teratoma.
    Horwich A, Easton D, Husband J, Nicholas D, Peckham MJ.
    Br J Urol; 1987 Jun; 59(6):578-83. PubMed ID: 2446691
    [Abstract] [Full Text] [Related]

  • 12. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
    Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ.
    Cancer Res; 1982 Nov; 42(11):4855-61. PubMed ID: 6181870
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Fléchon A.
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours.
    Horwich A, Brada M, Nicholls J, Jay G, Hendry WF, Dearnaley D, Peckham MJ.
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):177-84. PubMed ID: 2467806
    [Abstract] [Full Text] [Related]

  • 16. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
    Bosl GJ, Head MD.
    Int J Biol Markers; 1994 Feb; 9(1):25-8. PubMed ID: 7519650
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
    Seckl MJ, Rustin GJ, Bagshawe KD.
    Br J Cancer; 1990 Jun; 61(6):916-8. PubMed ID: 1695522
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.